Teva Sues FDA For Excluding Copaxone From BLA Transition

Israeli Firm Wants To Use Biosimilar Litigation Process

 
• By Brenda Sandburg
  
Medical needles of Copaxone
Teva Wants Copaxone To Be Deemed A Biologic • Source: Shutterstock

More from Legal & IP

More from Generics Bulletin